Transungual Drug Delivery: An Overview
... straightforward, and have the most in vivo experience associated with them. In contrast, many of the chemical and physical methods discussed are still in the in vitro stages of development; laboratory studies are currently examining these techniques using human nail samples. The goal of topical ther ...
... straightforward, and have the most in vivo experience associated with them. In contrast, many of the chemical and physical methods discussed are still in the in vitro stages of development; laboratory studies are currently examining these techniques using human nail samples. The goal of topical ther ...
WHO monographs on medicinal plants commonly used in the Newly
... should be set in accordance with national requirements by the appropriate authorities of Member States. Each medicinal plant and the specific plant part used as crude drug material contain active or major chemical constituents with a characteristic profile that can be used for chemical quality contr ...
... should be set in accordance with national requirements by the appropriate authorities of Member States. Each medicinal plant and the specific plant part used as crude drug material contain active or major chemical constituents with a characteristic profile that can be used for chemical quality contr ...
Lipid nanoparticles for topical and transdermal application for
... hair. This abnormality affects the hair follicle and causes its shed. There are different types of alopecia according to its cause, but one of the most common types – androgenic alopecia – affects up to half of the Caucasian male population by middle age, and almost all Caucasian men by old age (95% ...
... hair. This abnormality affects the hair follicle and causes its shed. There are different types of alopecia according to its cause, but one of the most common types – androgenic alopecia – affects up to half of the Caucasian male population by middle age, and almost all Caucasian men by old age (95% ...
ICH Q3D Guideline (Elemental Impurities)
... establishment of a Permitted Daily Exposure (PDE) for each element of toxicological concern, and development of controls designed to limit the inclusion of elemental impurities in drug products to levels at or below the PDE. It is not expected that an applicant tightens the limits based on process c ...
... establishment of a Permitted Daily Exposure (PDE) for each element of toxicological concern, and development of controls designed to limit the inclusion of elemental impurities in drug products to levels at or below the PDE. It is not expected that an applicant tightens the limits based on process c ...
July 28, 2014 Margaret A. Hamburg, MD
... “generally recognized as safe and effective (GRASE)” under specific conditions. 25 Such regulations are referred to as “final monographs.” 26 Creation of a drug monograph requires several rulemaking steps, including publication in the Federal Register of a tentative final monograph, which precedes p ...
... “generally recognized as safe and effective (GRASE)” under specific conditions. 25 Such regulations are referred to as “final monographs.” 26 Creation of a drug monograph requires several rulemaking steps, including publication in the Federal Register of a tentative final monograph, which precedes p ...
PHARMACEUTICAL IMPURITY ANALYSIS SOLUTIONS
... known, unknown, volatile, or non-volatile compounds with sources including starting materials, intermediates, unintended by-products, and degradation products. They may also arise from racemization, or contamination of one enantiomeric form with another. In all cases they can result in undesired bio ...
... known, unknown, volatile, or non-volatile compounds with sources including starting materials, intermediates, unintended by-products, and degradation products. They may also arise from racemization, or contamination of one enantiomeric form with another. In all cases they can result in undesired bio ...
Neuroscience of psychoactive substance use and dependence Neur
... contributed reviews that formed the basis for the final report: Helena M. T. Barros, Federal University of Medical Sciences Foundation, Porto Alegre, Brazil; Lucy Carter, Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland, Australia; David Collier, Section of Genetics ...
... contributed reviews that formed the basis for the final report: Helena M. T. Barros, Federal University of Medical Sciences Foundation, Porto Alegre, Brazil; Lucy Carter, Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland, Australia; David Collier, Section of Genetics ...
Malaria Prevention (NDOH 2009)
... Disclaimer This material is intended for use by healthcare professionals. It has been compiled from information currently available, and although the greatest care has been taken, the Department of Health and its Malaria Advisory Group do not accept responsibility for errors or omissions. The guidel ...
... Disclaimer This material is intended for use by healthcare professionals. It has been compiled from information currently available, and although the greatest care has been taken, the Department of Health and its Malaria Advisory Group do not accept responsibility for errors or omissions. The guidel ...
product monograph - Takeda Canada Inc.
... and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines (see DOSAGE AND ADMIN ...
... and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines (see DOSAGE AND ADMIN ...
Delirium in the Elderly
... year of hospital discharge. In-hospital mortality rates for patients with delirium range from 22% to 76%, similar to mortality rates for acute myocardial infarction or sepsis. Patients older than 70 years who experienced delirium during hospitalization have a 62% increased risk of death at 1 year. I ...
... year of hospital discharge. In-hospital mortality rates for patients with delirium range from 22% to 76%, similar to mortality rates for acute myocardial infarction or sepsis. Patients older than 70 years who experienced delirium during hospitalization have a 62% increased risk of death at 1 year. I ...
... the chest tube to 18 patients and reported that the treatment was effective in 17 patients (94%). These workers attributed the efficacy of the instillation of nitrogen mustard to the production of a chemical pleuritis that resulted in an effective pleurodesis. ANDERSON et al. [22], however, reported ...
Recent changes in Europe`s MDMA/ecstasy market
... production is destined for internal markets, with Germany and the United Kingdom being the most common destinations. There is no evidence of MDMA being imported into the European Union (EU). Assessing recent trends in MDMA seizures is difficult due to the absence of data from some countries that are ...
... production is destined for internal markets, with Germany and the United Kingdom being the most common destinations. There is no evidence of MDMA being imported into the European Union (EU). Assessing recent trends in MDMA seizures is difficult due to the absence of data from some countries that are ...
2012 Medical Marijuana for the Treatment of Migraine Headaches:
... use of marijuana and ectasy. There were two articles reporting a cross sectional study. One appears to be a subset of the other but this is not clear. Neither directly addresses the clinical question of effectiveness and both studies are of extremely low quality. ...
... use of marijuana and ectasy. There were two articles reporting a cross sectional study. One appears to be a subset of the other but this is not clear. Neither directly addresses the clinical question of effectiveness and both studies are of extremely low quality. ...
Chestal ® Cough Monograph - Boiron USA for Health Care
... cough-relieving properties and a pleasant taste. Chestal and Children’s Chestal are over-the-counter homeopathic medicines that do not cause drowsiness and are non-habit forming. They can be used by patients taking other medications. Children’s Chestal is recommended for children 2 years of age and ...
... cough-relieving properties and a pleasant taste. Chestal and Children’s Chestal are over-the-counter homeopathic medicines that do not cause drowsiness and are non-habit forming. They can be used by patients taking other medications. Children’s Chestal is recommended for children 2 years of age and ...
Severe Intoxication with the Veterinary Tranquilizer Xylazine in
... metabolized to nearly 20 metabolites, with only 8% of the administered dose being eliminated in the urine as unchanged substance (13). The major metabolite is 2,6-dimethylaniline. In spite of the high dose administered, we did not find any metabolites in the urine of the patient. The xylazine metabo ...
... metabolized to nearly 20 metabolites, with only 8% of the administered dose being eliminated in the urine as unchanged substance (13). The major metabolite is 2,6-dimethylaniline. In spite of the high dose administered, we did not find any metabolites in the urine of the patient. The xylazine metabo ...
PrCIPRO® XL
... usually acidic. Crystals have been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded. In patients with reduced renal funct ...
... usually acidic. Crystals have been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded. In patients with reduced renal funct ...
Word - corporate
... days in SCD subjects). We are evaluating the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, of GBT440, as well as exploratory markers of SCD activity, including anti-hemolytic effects and SCD-related clinical effects. We reported initial results from our Phase 1/2 clinic ...
... days in SCD subjects). We are evaluating the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, of GBT440, as well as exploratory markers of SCD activity, including anti-hemolytic effects and SCD-related clinical effects. We reported initial results from our Phase 1/2 clinic ...
[Product Monograph Template - Standard]
... 30%. The effects of DOVOBET gel on calcium metabolism following treatment durations of more than 8 weeks have not been evaluated. ...
... 30%. The effects of DOVOBET gel on calcium metabolism following treatment durations of more than 8 weeks have not been evaluated. ...
diamorphine hydrochloride bp 5 mg lyophilisate for solution for
... suitable justification for the absence of an environmental risk assessment, stating that the proposed medicinal product will not be administered at higher dosage levels, for longer durations or for different indications than existing, marketed products. As such, the use of the proposed product is un ...
... suitable justification for the absence of an environmental risk assessment, stating that the proposed medicinal product will not be administered at higher dosage levels, for longer durations or for different indications than existing, marketed products. As such, the use of the proposed product is un ...
11127sgp03
... In 1956, paracetamol went on sale in the United Kingdom under the trade name Panadol which is a famous brand called “必理痛” in Hong Kong. ...
... In 1956, paracetamol went on sale in the United Kingdom under the trade name Panadol which is a famous brand called “必理痛” in Hong Kong. ...
PRODUCT INFORMATION METHADONE SYRUP
... the likelihood of methadone toxicity. In addition to compounds that may decrease the metabolism of methadone, extreme caution is necessary when any drug known to have the potential to prolong the QT interval is prescribed in conjunction with methadone (see PRECAUTIONS). Interactions may occur with m ...
... the likelihood of methadone toxicity. In addition to compounds that may decrease the metabolism of methadone, extreme caution is necessary when any drug known to have the potential to prolong the QT interval is prescribed in conjunction with methadone (see PRECAUTIONS). Interactions may occur with m ...
Critical Reviews in Oral Biology & Medicine
... was no adrenal suppression, as assessed by measurements of serum and urine cortisol levels in patients with erosive lichen planus as well as a control group. Nevertheless, the prolonged use of topical steroids on oral mucous membrane lesions necessitates careful and frequent follow-up examinations. ...
... was no adrenal suppression, as assessed by measurements of serum and urine cortisol levels in patients with erosive lichen planus as well as a control group. Nevertheless, the prolonged use of topical steroids on oral mucous membrane lesions necessitates careful and frequent follow-up examinations. ...
Product Information for Sitagliptin/Metformin
... (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insu ...
... (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insu ...
Microfluidic-Based Multi-Organ Platforms for Drug Discovery
... standards of in vitro culture models but their application for the systemic analysis of the crosstalk of multiple organs is limited [10–12]. Microtechnology has significantly contributed to the development of biomimetic in vitro models for predicting the drug efficacy with higher reliability than tr ...
... standards of in vitro culture models but their application for the systemic analysis of the crosstalk of multiple organs is limited [10–12]. Microtechnology has significantly contributed to the development of biomimetic in vitro models for predicting the drug efficacy with higher reliability than tr ...
Bad Pharma
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.